Three years after its implementation, this model has been integrated into the care pathway and is becoming a benchmark in digital health in the field of headaches.
To mark International Migraine Day of Action, which is celebrated on 12 September, the Clínic wishes to highlight this project as an example of how digital innovation can improve the care and quality of life of people suffering from this disease.
A new care pathway
The key to the project is a streamlined, digitized pathway that allows primary care professionals to identify and categorize patients with migraine from the first visit. Using a QR code, patients complete an online survey that classifies the type of migraine and the degree of disability, and facilitates a quick referral tailored to the needs of each case.
This system, now fully implemented in all AISBE primary care centres, has helped improve accessibility, reduce diagnosis time, and avoid the chronification of many patients.
Patient education and empowerment
One of the project’s most important contributions has been to make therapeutic education a central part of the approach to migraine. The accumulated experience shows that specific training reduces the functional and emotional impact of the disease, and helps patients gain autonomy in their day-to-day management.
In order to continue along these lines, monthly telematic sessions have been created, given by nurses, aimed at patients referred through MigraAgile, which complement the face-to-face care and expand the options for support.
The Headache and Facial Pain Working Group stresses that MigraAgile is not only an innovative project, but is consolidating itself as a replicable model for other territories and pathologies. The seamless integration between primary and specialized care, the use of digital tools and the active role of patients pave the way towards more personalized and sustainable care.
The objectives for the future are to ensure that all the doctors at the different primary care centres (CAPs) in the AISBE are familiar with the application, to assess whether it is useful to have designated medical and nursing staff as points of reference in each CAP, to expand MigraAgile to new territories, to reinforce the training of health professionals, and to continue to invest in research into new treatments and approach strategies. All this, with a firm commitment to destigmatizing migraines and guaranteeing comprehensive care that not only takes into account the medical aspects, but also the social and emotional ones.
An invisible but treatable disease
A migraine is not just a headache. It is a chronic and disabling neurological disease that affects 1 in 7 people worldwide. Despite its high prevalence, it continues to be an underdiagnosed and stigmatized condition. Migraine can be diagnosed, treated and controlled, and all patients deserve care tailored to their needs.
With over 2,500 patients treated in 2025, the Headache and Facial Pain Unit at the Clínic offers a wide range of treatments, including:
• Botulinum toxin type A: used since 2012 for the prevention of chronic migraine.
• Monoclonal antibodies against CGRP: innovative drugs with high preventive efficacy.
• CGRP receptor blockers (Atogepant and Rimegepant): oral preventives.
• Cranial nerve blocks: for resistant or complex cases.
